Abstract
We studied the effects of continuous subcutaneous infusion of octreotide (100 μ/day for 5 days) on glycaemic values, counterregulatory hormones secretion, hepatic glucose production (HGP) and glucose disposal during an euglycaemic clamp in 7 C-peptide-negative type 1 diabetic patients and 7 C- peptide positive insulin-treated type 2 diabetic patients. In type 1, but not type 2 diabetic patients, octreotide significantly reduced glycaemic values (P <0.005) and also diminished HGP during an euglycaemic clamp (P <0.005). However, insulin stimulated global glucose uptake remained unchanged. GH, glucagon, IGF-I, IGFBP-3 levels, were significantly lowered by octreotide in both type 1 and type 2 diabetic patients whereas cortisol and epinephrine remained unmodified. Moreover in type 2 diabetic patients both basal (P <0.05) and after-meal (P <0.01) C-peptide secretion was reduced by octreotide. These data point to different metabolic effects of octreotide in type 1 versus type 2 diabetic patients with the drug only being able to reduce glycaemic values and HGP in the former but not in the latter subjects. The failure of octreotide to diminish glycaemic values and HGP in type 2 diabetic patients in spite of its ability to lower GH and glucagon may probably depend on temporary blockage of residual endogenous insulin secretion induced by octreotide administration.
| Original language | English |
|---|---|
| Pages (from-to) | 81-89 |
| Number of pages | 9 |
| Journal | Diabetes Research and Clinical Practice |
| Volume | 38 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Nov 1997 |
Fingerprint
Keywords
- Counterregulatory hormones
- Hepatic glucose production
- Octreotide
- Type 1 diabetes
- Type 2 diabetes
ASJC Scopus subject areas
- Endocrinology
- Endocrinology, Diabetes and Metabolism
Cite this
Effects of octreotide on glycaemic control, glucose disposal, hepatic glucose production and counterregulatory hormones secretion in type 1 and type 2 insulin treated diabetic patients. / Lunetta, M.; Di Mauro, M.; Le Moli, R.; Nicoletti, F.
In: Diabetes Research and Clinical Practice, Vol. 38, No. 2, 11.1997, p. 81-89.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effects of octreotide on glycaemic control, glucose disposal, hepatic glucose production and counterregulatory hormones secretion in type 1 and type 2 insulin treated diabetic patients
AU - Lunetta, M.
AU - Di Mauro, M.
AU - Le Moli, R.
AU - Nicoletti, F.
PY - 1997/11
Y1 - 1997/11
N2 - We studied the effects of continuous subcutaneous infusion of octreotide (100 μ/day for 5 days) on glycaemic values, counterregulatory hormones secretion, hepatic glucose production (HGP) and glucose disposal during an euglycaemic clamp in 7 C-peptide-negative type 1 diabetic patients and 7 C- peptide positive insulin-treated type 2 diabetic patients. In type 1, but not type 2 diabetic patients, octreotide significantly reduced glycaemic values (P <0.005) and also diminished HGP during an euglycaemic clamp (P <0.005). However, insulin stimulated global glucose uptake remained unchanged. GH, glucagon, IGF-I, IGFBP-3 levels, were significantly lowered by octreotide in both type 1 and type 2 diabetic patients whereas cortisol and epinephrine remained unmodified. Moreover in type 2 diabetic patients both basal (P <0.05) and after-meal (P <0.01) C-peptide secretion was reduced by octreotide. These data point to different metabolic effects of octreotide in type 1 versus type 2 diabetic patients with the drug only being able to reduce glycaemic values and HGP in the former but not in the latter subjects. The failure of octreotide to diminish glycaemic values and HGP in type 2 diabetic patients in spite of its ability to lower GH and glucagon may probably depend on temporary blockage of residual endogenous insulin secretion induced by octreotide administration.
AB - We studied the effects of continuous subcutaneous infusion of octreotide (100 μ/day for 5 days) on glycaemic values, counterregulatory hormones secretion, hepatic glucose production (HGP) and glucose disposal during an euglycaemic clamp in 7 C-peptide-negative type 1 diabetic patients and 7 C- peptide positive insulin-treated type 2 diabetic patients. In type 1, but not type 2 diabetic patients, octreotide significantly reduced glycaemic values (P <0.005) and also diminished HGP during an euglycaemic clamp (P <0.005). However, insulin stimulated global glucose uptake remained unchanged. GH, glucagon, IGF-I, IGFBP-3 levels, were significantly lowered by octreotide in both type 1 and type 2 diabetic patients whereas cortisol and epinephrine remained unmodified. Moreover in type 2 diabetic patients both basal (P <0.05) and after-meal (P <0.01) C-peptide secretion was reduced by octreotide. These data point to different metabolic effects of octreotide in type 1 versus type 2 diabetic patients with the drug only being able to reduce glycaemic values and HGP in the former but not in the latter subjects. The failure of octreotide to diminish glycaemic values and HGP in type 2 diabetic patients in spite of its ability to lower GH and glucagon may probably depend on temporary blockage of residual endogenous insulin secretion induced by octreotide administration.
KW - Counterregulatory hormones
KW - Hepatic glucose production
KW - Octreotide
KW - Type 1 diabetes
KW - Type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=0031426803&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031426803&partnerID=8YFLogxK
U2 - 10.1016/S0168-8227(97)00094-6
DO - 10.1016/S0168-8227(97)00094-6
M3 - Article
VL - 38
SP - 81
EP - 89
JO - Diabetes Research and Clinical Practice
JF - Diabetes Research and Clinical Practice
SN - 0168-8227
IS - 2
ER -